Cannabis regulators in several US states say the Drug Enforcement Administration (DEA) has failed to give them guidance on the Trump administration’s move to reschedule marijuana, as first reported by Marijuana Moment.

Officials in Georgia, Vermont and California have all said in recent public meetings that they are struggling to understand what the change means for business registration, taxes and product packaging.

What changed

In April, Attorney General Todd Blanche issued an order moving marijuana products regulated under a state medical cannabis licence, along with marijuana products approved by the Food and Drug Administration, from Schedule I to Schedule III of the Controlled Substances Act. According to Marijuana Moment, a DEA hearing that has recently finished taking testimony is considering broader rescheduling. The DEA has also opened forms for cannabis businesses to register for federal protections in line with the change.

Georgia: labelling rules

Last week Georgia regulators approved changes to the state’s medical cannabis rules, including on warning labels. The federal order says medical marijuana is subject to a rule requiring a clear warning that it is a crime to transfer the drug to anyone other than the patient.

Andrew Turnage, executive director of the Georgia Access to Medical Cannabis Commission, said his staff had asked the DEA for help aligning state wording with the federal requirement, so licensees would not need duplicate labelling. He said the DEA told them it could not comment on the proposed rule language.

Mr Turnage said regional DEA officials had been professional, but that agency leadership needed to communicate better. “Really it’s past time and high time for DEA to communicate with state regulators,” he said.

Vermont and California

At a separate meeting in Vermont, Cannabis Control Board chair James Pepper said an association of state regulators had compiled a list of key questions for the DEA and received “radio silence”. He said regional offices had been good partners but had no more answers, and suggested decisions were being made at headquarters.

Board commissioner Julie Hulburd said the state needed guidance from both the DEA and the tax department, adding that everyone was “in the figure it out mode”.

Clint Kellum, director of California’s Department of Cannabis Control, said last month that the state had received no formal updates from DEA headquarters on implementing the order. He said other states were beginning to see DEA inspections of registered businesses, with some regional variation in approach, and that the agency appeared more focused on states with clear medical cannabis programmes than mixed states such as California.

Gillian Schauer, executive director of the Cannabis Regulators Association, wrote in an op-ed for Marijuana Moment that the DEA had “not meaningfully engaged” states, even though implementation will depend heavily on state systems.

Why it matters in the UK

The US is one of the world’s largest cannabis markets, and its federal policy shifts are closely watched internationally. In the UK, cannabis remains a Class B drug under the Misuse of Drugs Act 1971, although specialist doctors have been able to prescribe cannabis-based medicines since 1 November 2018.

The DEA has not been quoted in the reports responding to the regulators’ complaints.